Coherus BioSciences (CHRS) Set to Announce Earnings on Wednesday

Coherus BioSciences (NASDAQ:CHRS) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Coherus BioSciences to post earnings of ($0.10) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. The company had revenue of $64.98 million for the quarter, compared to the consensus estimate of $57.08 million. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus BioSciences Stock Performance

Shares of NASDAQ:CHRS opened at $0.72 on Monday. The firm has a market cap of $83.30 million, a price-to-earnings ratio of -1.81 and a beta of 0.69. The firm has a fifty day moving average price of $1.06 and a 200 day moving average price of $1.49. Coherus BioSciences has a fifty-two week low of $0.71 and a fifty-two week high of $3.73.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CHRS shares. StockNews.com lowered Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. UBS Group downgraded Coherus BioSciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $4.00 to $1.50 in a research report on Friday, August 16th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Coherus BioSciences in a research report on Monday, September 16th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.13.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.